Neuren Pharmaceuticals (ASX:NEU) Reports Record Financial Performance and Expansion Plans
Financial Performance
Neuren Pharmaceuticals reported a record comprehensive income of A$166 million in 2024, with A$445 million income from DAYBUE at a 100% pre-tax margin, resulting in A$341 million cash at 31 March 2025 from operations.
Operational Highlights
DAYBUE achieved net sales of US$348 million in its first full year, with Acadia expanding its presence in the USA and forecasting continued growth in 2025. A $50 million share buy-back program commenced in November last year remains ongoing.
Clinical Developments
Positive Phase 2 trial results for NNZ-2591 in Pitt Hopkins, Angelman, and Phelan-McDermid syndromes validate its potential impact on neurodevelopmental conditions. Neuren is moving forward with Phase 3 trials for Phelan-McDermid syndrome.
Future Outlook
Neuren plans to expand DAYBUE’s reach into Canada, Europe, Japan, and other regions, providing substantial long-term growth opportunities. The company maintains confidence in adding shareholder value through ongoing royalties and milestone payments.
Executive Comments
CEO Jon Pilcher stated, “I’m not alone in holding this view, as mentioned earlier all 9 analysts that cover our company have published detailed independent analysis of the upside they see in Neuren.”
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
